Death receptor Fas (CD95) signaling in the central nervous system: tuning neuroplasticity?

Trends in Neurosciences

Volumn 31, Issue 9, 2008, Pages 478-486

  Reich, Arno ^a   Spering, Christopher ^a   Schulz, Jörg B ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DAXX PROTEIN; FAS ANTIGEN; FAS APOPTOTIC INHIBITORY MOLECULE; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS ASSOCIATED PHOSPHATASE 1; FAS LIGAND; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN ENRICHED IN ASTROCYTE 15; PROTEIN; PROTEIN KINASE B; RECEPTOR INTERACTING PROTEIN; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; X LINKED INHIBITOR OF APOPTOSIS 1; X LINKED INHIBITOR OF APOPTOSIS 2;

ALLERGIC ENCEPHALOMYELITIS; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; AVULSION INJURY; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN MITOCHONDRION; CELL TYPE; CENTRAL NERVOUS SYSTEM; CRUSH TRAUMA; DEGENERATIVE DISEASE; ENCEPHALITIS; EXPERIMENTAL MODEL; FACIAL NERVE INJURY; HUMAN; METABOLIC STRESS; MIDDLE CEREBRAL ARTERY OCCLUSION; MULTIPLE SCLEROSIS; NERVE CELL NECROSIS; NERVE CELL NETWORK; NERVE CELL PLASTICITY; NERVE FIBER GROWTH; NERVE INJURY; NEUROLOGIC DISEASE; NEUROPHYSIOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SCIATIC NEUROPATHY; SIGNAL TRANSDUCTION; SPINAL CORD INJURY;

ANIMALS; ANTIGENS, CD; APOPTOSIS; CENTRAL NERVOUS SYSTEM; FAS LIGAND PROTEIN; HUMANS; NEURONAL PLASTICITY; SIGNAL TRANSDUCTION;

EID: 50249100375     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2008.06.007     Document Type: Review

References (70)

1. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science 267 (1995) 1456-1462
2. Eguchi K. Apoptosis in autoimmune diseases. Intern. Med. 40 (2001) 275-284
3. Lambert C., et al. Fas-beyond death: a regenerative role for Fas in the nervous system. Apoptosis 8 (2003) 551-562
4. Wajant H., et al. Non-apoptotic Fas signaling. Cytokine Growth Factor Rev. 14 (2003) 53-66
5. Choi C., and Benveniste E.N. Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses. Brain Res. Brain Res. Rev. 44 (2004) 65-81
6. Tan Z., et al. Increased expression of Fas (CD95/APO-1) in adult rat brain after kainate-induced seizures. Neuroreport 12 (2001) 1979-1982
7. Yoshino O., et al. The role of Fas-mediated apoptosis after traumatic spinal cord injury. Spine 29 (2004) 1394-1404
8. Demjen D., et al. Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury. Nat. Med. 10 (2004) 389-395
9. Casha S., et al. FAS deficiency reduces apoptosis, spares axons and improves function after spinal cord injury. Exp. Neurol. 196 (2005) 390-400
10. Ackery A., et al. Inhibition of Fas-mediated apoptosis through administration of soluble Fas receptor improves functional outcome and reduces posttraumatic axonal degeneration after acute spinal cord injury. J. Neurotrauma 23 (2006) 604-616
11. Beier C.P., et al. CD95/Fas mediates cognitive improvement after traumatic brain injury. Cell Res. 17 (2007) 732-734
12. Sabelko K.A., et al. Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system. J. Immunol. 159 (1997) 3096-3099
13. Waldner H., et al. Fas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis. J. Immunol. 159 (1997) 3100-3103
14. Sabelko-Downes K.A., et al. Role of Fas-FasL interactions in the pathogenesis and regulation of autoimmune demyelinating disease. J. Neuroimmunol. 100 (1999) 42-52
15. Dittel B.N., et al. Evidence for Fas-dependent and Fas-independent mechanisms in the pathogenesis of experimental autoimmune encephalomyelitis. J. Immunol. 162 (1999) 6392-6400
16. Hovelmeyer N., et al. Apoptosis of oligodendrocytes via Fas and TNF-R1 is a key event in the induction of experimental autoimmune encephalomyelitis. J. Immunol. 175 (2005) 5875-5884
17. Martin-Villalba A., et al. CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J. Neurosci. 19 (1999) 3809-3817
18. Rosenbaum D.M., et al. Fas (CD95/APO-1) plays a role in the pathophysiology of focal cerebral ischemia. J. Neurosci. Res. 61 (2000) 686-692
19. Martin-Villalba A., et al. Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ. 8 (2001) 679-686
20. Graham E.M., et al. Neonatal mice lacking functional Fas death receptors are resistant to hypoxic-ischemic brain injury. Neurobiol. Dis. 17 (2004) 89-98
21. Ugolini G., et al. Fas/tumor necrosis factor receptor death signaling is required for axotomy-induced death of motoneurons in vivo. J. Neurosci. 23 (2003) 8526-8531
22. Martin L.J., et al. Adult motor neuron apoptosis is mediated by nitric oxide and Fas death receptor linked by DNA damage and p53 activation. J. Neurosci. 25 (2005) 6449-6459
23. Raoul C., et al. Programmed cell death of embryonic motoneurons triggered through the Fas death receptor. J. Cell Biol. 147 (1999) 1049-1062
24. Raoul C., et al. Chronic activation in presymptomatic amyotrophic lateral sclerosis (ALS) mice of a feedback loop involving Fas, Daxx, and FasL. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 6007-6012
25. Petri S., et al. Loss of Fas ligand-function improves survival in G93A-transgenic ALS mice. J. Neurol. Sci. 251 (2006) 44-49
26. Locatelli F., et al. Fas small interfering RNA reduces motoneuron death in amyotrophic lateral sclerosis mice. Ann. Neurol. 62 (2007) 81-92
27. Morishima Y., et al. β-Amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J. Neurosci. 21 (2001) 7551-7560
28. Su J.H., et al. Fas and Fas ligand are associated with neuritic degeneration in the AD brain and participate in β-amyloid-induced neuronal death. Neurobiol. Dis. 12 (2003) 182-193
29. Hikawa N., et al. Delayed neurite regeneration and its improvement by nerve growth factor (NGF) in dorsal root ganglia from MRL-lpr/lpr mice in vitro. J. Neurol. Sci. 149 (1997) 13-17
30. Desbarats J., et al. Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat. Cell Biol. 5 (2003) 118-125
31. Zuliani C., et al. Control of neuronal branching by the death receptor CD95 (Fas/Apo-1). Cell Death Differ. 13 (2006) 31-40
32. Sakic B., et al. Progressive atrophy of pyramidal neuron dendrites in autoimmune MRL-lpr mice. J. Neuroimmunol. 87 (1998) 162-170
33. Hayley S., et al. Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neurosci. 24 (2004) 2045-2053
34. Landau A.M., et al. Defective Fas expression exacerbates neurotoxicity in a model of Parkinson's disease. J. Exp. Med. 202 (2005) 575-581
35. Hao Z., et al. T cell-specific ablation of Fas leads to Fas ligand-mediated lymphocyte depletion and inflammatory pulmonary fibrosis. J. Exp. Med. 199 (2004) 1355-1365
36. Desbarats J., and Newell M.K. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat. Med. 6 (2000) 920-923
37. Peter M.E., et al. The CD95 receptor: apoptosis revisited. Cell 129 (2007) 447-450
38. Tran S.E., et al. MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J. Biol. Chem. 276 (2001) 16484-16490
39. Park S.M., et al. Nonapoptotic functions of FADD-binding death receptors and their signaling molecules. Curr. Opin. Cell Biol. 17 (2005) 610-616
40. Peter M.E., et al. Does CD95 have tumor promoting activities?. Biochim. Biophys. Acta 1755 (2005) 25-36
41. Kleber S., et al. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 13 (2008) 235-248
42. Ruan W., et al. A novel juxtamembrane domain in TNF receptor superfamily molecules activates Rac1 and controls neurite growth. Mol. Biol. Cell (2008). http://www.molbiolcell.org 10.1091/mbc.E08-02-0161
43. Ricci-Vitiani L., et al. Absence of caspase 8 and high expression of PED protect primitive neural cells from cell death. J. Exp. Med. 200 (2004) 1257-1266
44. Ceccatelli S., et al. Neural stem cells and cell death. Toxicol. Lett. 149 (2004) 59-66
45. Sun M., and Fink P.J. A new class of reverse signaling costimulators belongs to the TNF family. J. Immunol. 179 (2007) 4307-4312
46. Peter M.E., and Krammer P.H. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 10 (2003) 26-35
47. Safa A.R., et al. Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr. Cancer Drug Targets 8 (2008) 37-46
48. Kataoka T., and Tschopp J. N-terminal fragment of c-FLIP(L) processed by caspase 8 specifically interacts with TRAF2 and induces activation of the NF-κB signaling pathway. Mol. Cell. Biol. 24 (2004) 2627-2636
49. Payton K.S., et al. Antioxidant status alters levels of Fas-associated death domain-like IL-1B-converting enzyme inhibitory protein following neonatal hypoxia-ischemia. Dev. Neurosci. 29 (2007) 403-411
50. Taoufik E., et al. FLIP(L) protects neurons against in vivo ischemia and in vitro glucose deprivation-induced cell death. J. Neurosci. 27 (2007) 6633-6646
51. Sharif A., et al. The expression of PEA-15 (phosphoprotein enriched in astrocytes of 15 kDa) defines subpopulations of astrocytes and neurons throughout the adult mouse brain. Neuroscience 126 (2004) 263-275
52. Hao C., et al. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apoptosis in human malignant glioma cells. Cancer Res. 61 (2001) 1162-1170
53. Banno Y., et al. Involvement of phospholipase D in sphingosine 1-phosphate-induced activation of phosphatidylinositol 3-kinase and Akt in Chinese hamster ovary cells overexpressing EDG3. J. Biol. Chem. 276 (2001) 35622-35628
54. Eckert A., et al. The PEA-15/PED protein protects glioblastoma cells from glucose deprivation-induced apoptosis via the ERK/MAP kinase pathway. Oncogene 27 (2008) 1155-1166
55. Renganathan H., et al. Phosphorylation of PEA-15 switches its binding specificity from ERK/MAPK to FADD. Biochem. J. 390 (2005) 729-735
56. Segura M.F., et al. The long form of Fas apoptotic inhibitory molecule is expressed specifically in neurons and protects them against death receptor-triggered apoptosis. J. Neurosci. 27 (2007) 11228-11241
57. Sole C., et al. The death receptor antagonist FAIM promotes neurite outgrowth by a mechanism that depends on ERK and NF-κ B signaling. J. Cell Biol. 167 (2004) 479-492
58. Bette M., et al. Constitutive expression of p55TNFR mRNA and mitogen-specific up-regulation of TNF α and p75TNFR mRNA in mouse brain. J. Comp. Neurol. 465 (2003) 417-430
59. Somia N.V., et al. LFG: an anti-apoptotic gene that provides protection from Fas-mediated cell death. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 12667-12672
60. Beier C.P., et al. FasL (CD95L/APO-1L) resistance of neurons mediated by phosphatidylinositol 3-kinase-Akt/protein kinase B-dependent expression of lifeguard/neuronal membrane protein 35. J. Neurosci. 25 (2005) 6765-6774
61. Fernandez M., et al. Lifeguard/neuronal membrane protein 35 regulates Fas ligand-mediated apoptosis in neurons via microdomain recruitment. J. Neurochem. 103 (2007) 190-203
62. Schweitzer B., et al. Neural membrane protein 35 (NMP35): a novel member of a gene family which is highly expressed in the adult nervous system. Mol. Cell. Neurosci. 11 (1998) 260-273
63. Schweitzer B., et al. Neural membrane protein 35/Lifeguard is localized at postsynaptic sites and in dendrites. Brain Res. Mol. Brain Res. 107 (2002) 47-56
64. Eramo A., et al. CD95 death-inducing signaling complex formation and internalization occur in lipid rafts of type I and type II cells. Eur. J. Immunol. 34 (2004) 1930-1940
65. Davis A.R., et al. FasL, Fas, and death-inducing signaling complex (DISC) proteins are recruited to membrane rafts after spinal cord injury. J. Neurotrauma 24 (2007) 823-834
66. Foehr E.D., et al. FAS associated phosphatase (FAP-1) blocks apoptosis of astrocytomas through dephosphorylation of FAS. J. Neurooncol. 74 (2005) 241-248
67. Vassilev A.O., and Uckun F.M. Therapeutic potential of inhibiting Bruton's tyrosine kinase (BTK). Curr. Pharm. Des. 10 (2004) 1757-1766
68. Song Y., and Jacob C.O. The mouse cell surface protein TOSO regulates Fas/Fas ligand-induced apoptosis through its binding to Fas-associated death domain. J. Biol. Chem. 280 (2005) 9618-9626
69. Tran S.E., et al. Instant decisions: transcription-independent control of death-receptor-mediated apoptosis. Trends Biochem. Sci. 29 (2004) 601-608
70. Siren A.L., et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 4044-4049